Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Wohns

Interventional Cardiology Grand Rapids, MI Medical Doctor

NPI 1588655922 CMS profile 26614

2900 Bradford St Ne, Grand Rapids, MI 49525

Open in the dashboard

General payments

$128,593

159 records reported · program years 2019–2025

Research payments

$217

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$19,234

4 holdings reported · through program year 2025

Research they led as principal investigator

$1,000 paid to institutions, not to them · program year 2025

Through program year 2025, David Wohns of Grand Rapids, MI is reported in the CMS Open Payments database as having received $128,593 across 159 general payments and $217 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $19,234 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,911 19
2024 General $14,830 27
2023 General $1,338 10
2023 Research $217 3
2022 General $21,663 44
2021 General $5,774 5
2020 General $477 2
2019 General $82,599 52
2023 Ownership $1,600 1
2022 Ownership $2,776 1
2021 Ownership $2,776 1
2019 Ownership $12,082 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Wohns
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to David Wohns were reported at $1,911. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year David Wohns Interventional Cardiology median Middle half National median
2019 $82,599 $1,097 $329–$3,048 $163
2020 $477 $473 $161–$1,480 $114
2021 $5,774 $677 $233–$1,827 $132
2022 $21,663 $978 $333–$2,724 $149
2023 $1,338 $1,136 $382–$2,986 $160
2024 $14,830 $1,181 $395–$3,326 $164
2025 $1,911 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $123,361 98 payments
  2. Medtronic, Inc. $4,112 33 payments
  3. Boston Scientific Corporation $507 13 payments
  4. Angel Medical Systems, Inc. $250 1 payment
  5. Chiesi USA, Inc. $156 5 payments
  6. Abbott Laboratories $78 3 payments
  7. HeartFlow, Inc. $37 1 payment
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $27 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $27 2 payments
  10. Cardiovascular Systems Inc. $22 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $87,750 19 payments
  2. Travel and Lodging $34,047 56 payments
  3. Food and Beverage $5,946 82 payments
  4. Consulting Fee $850 2 payments
Products named General payments · program years 2019–2025
  1. Impella $121,691 84 payments
  2. Micra $226 2 payments
  3. KENGREAL $156 5 payments
  4. CLEVIPREX $156 5 payments
  5. General - Balloon Catheters $148 1 payment
  6. General - Therapies $72 1 payment
  7. AVVIGO Guidance System $70 3 payments
  8. FFRct $37 1 payment
  9. General Therapies $34 1 payment
  10. LifeVest $27 1 payment
  11. Other $195 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $217 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,144

Median for Interventional Cardiology: 2,236

Drug cost

$231,557

Median for Interventional Cardiology: $380,412

Branded share of claims

23.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 84 $108,435
Entresto Sacubitril/Valsartan Brand 38 $42,160
Xarelto Rivaroxaban Brand 19 $25,915
Jardiance Empagliflozin Brand 20 $19,558
Brilinta Ticagrelor Brand 16 $14,423
Metoprolol Succinate Generic 120 $3,825
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 13 $2,807
Atorvastatin Calcium Generic 149 $2,753
Rosuvastatin Calcium Generic 81 $1,754
Carvedilol Generic 94 $1,701

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$26,753

Medicare's payments for the services billed

Medicare patients

189

Average age 72

Services billed

300

80 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 44%
Heart failure 40%
Diabetes 39%
Atrial fibrillation 34%
Chronic kidney disease 31%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CLEVIPREX
  • CHIESI USA, INC. $33
$33 — —
KENGREAL
  • CHIESI USA, INC. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record